Johnson & Johnson (JNJ) announced new longer-term follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating RYBREVANT (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET. The study assessed RYBREVANT in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.
Results demonstrated that more than 70 percent of patients in the first-line subgroup responded to treatment with amivantamab plus chemotherapy, with most responses lasting beyond 16 months. These findings highlight the potential of RYBREVANT to deliver durable benefit in a difficult-to-treat patient population.
Notably, encouraging responses were also observed in patients with liver metastases, a group that typically faces poorer outcomes with colorectal cancer. The study further showed low rates of treatment-related discontinuations, underscoring the tolerability of the regimen.
The promising anti-tumor activity and durability of responses support continued investigation of RYBREVANT in ongoing Phase 3 studies for both first- and second-line colorectal cancer treatment.
Johnson & Johnson closed trading on January 9 at $204.39, down $1.36 or 0.66% during regular market hours. In after-hours trading, the stock edged higher to $204.98, gaining $0.59 or 0.29%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.